Companies: 10,795·Total market cap: $144.5T
Opus Genetics, Inc.

Opus Genetics, Inc.

IRDNASDAQHealthcare● Active
$4.05
+$0.02(+0.50%)
Market Cap$329651933
P/E Ratio
52W High$5.81
52W Low$0.9
Overview

Opus Genetics, Inc. (IRD) Shares Outstanding — Overview

Basic and diluted weighted average shares, YoY change, float context, and historical trend from SEC filings and FMP.

IRD · shares outstanding · updated Jun 9, 2026

Key metrics

Basic Shares Outstanding · Weighted average · fiscal year
622.2M +2229.05% YoY Change
FY · as of Dec 31, 2025 · Reported in USD
vs 26.7M in FY 2024
Diluted Shares Outstanding
622.2M
incl. options, RSUs, convertibles
Dilution Spread
+0.00%
Diluted vs Basic
YoY Change
+2229.05%
year-over-year
Float (Free Float)
34.5M
publicly tradable shares
42.4% of total
Source: FMP /income-statement · /shares-float · SEC 10-K / 10-QUpdated: 2026-06-09

Shares Outstanding Growth Rate

3-Year CAGRincreasing
+214.9%
2022 → 2025
5-Year CAGRincreasing
+166.1%
2020 → 2025
10-Year CAGR

Negative CAGR typically indicates share buyback or retirement activity. Interpret alongside Splits and Financials tabs. Splits / Financials

Shares outstanding history

↓ Decrease — typically buyback / retirement
↑ Increase — issuance / equity compensation
Latest
* most recent reported · FMP /income-statement · weightedAverageShsOut

Annual shares outstanding by year

FY 2025Latest
Diluted Shares: 622.2M
622.2M
+2229.05%
FY 2024
Diluted Shares: 26.7M
26.7M
+23.74%
FY 2023
Diluted Shares: 21.6M
21.6M
+8.32%
FY 2022
Diluted Shares: 20.6M
19.9M
+34.19%
FY 2021
Diluted Shares: 14.9M
14.9M
+218.65%
FMP /income-statement · weightedAverageShsOut · weightedAverageShsOutDilUnit: Billions (B)

Healthcare sector shares outstanding comparison

Shares Outstanding for similar companies or competitors in the Healthcare sector.

#SymbolCompanyShares (Basic)vs IRD
#1
Merck & Co., Inc.MRK
Merck & Co., Inc.
2.502B+302.1%
#2
Johnson & JohnsonJNJ
Johnson & Johnson
2.429B+290.3%
#3
AbbVie Inc.ABBV
AbbVie Inc.
1.780B+186.1%
#4
AstraZeneca PLCAZN
AstraZeneca PLC
1.550B+149.1%
#5
UnitedHealth Group IncorporatedUNH
UnitedHealth Group Incorporated
910.0M+46.3%
#6
Eli Lilly and CompanyLLY
Eli Lilly and Company
898.0M+44.3%
#7
Opus Genetics, Inc.IRD
Opus Genetics, Inc.YOU
622.2M

/company-screener · per-peer /income-statement · cache 86400s

Understanding Shares Outstanding

What Are Shares Outstanding? (Basic)

Opus Genetics, Inc. (IRD) shares outstanding is the total number of issued shares held by shareholders — the basis for Basic EPS and market capitalization. As of December 31, 2025, Opus Genetics, Inc. reports 622.2M basic shares outstanding (weighted average).

Basic vs. Diluted Shares Outstanding

Opus Genetics, Inc.'s basic shares outstanding (622.2M) represents currently issued shares. Diluted shares outstanding (622.2M) also includes potential shares from stock options, RSUs, and convertibles. Dilution spread: +0.00%.

Shares Outstanding vs. Float (Free Float)

Opus Genetics, Inc.'s float is 34.5M (42.4% of total shares outstanding) — shares freely available for public trading, excluding insider-held and restricted shares.

Float34.5M(42.4%)
Outstanding81.4M

Float data from /shares-float reflects the most recent SEC filing period-end. The weighted average shares (from /income-statement) may differ — this is a normal reporting window difference, not a data error.

FMP /income-statement · /shares-float · SEC EDGAR · USD

About shares outstanding & methodology

Opus Genetics, Inc. (IRD) shares outstanding history from 2019 to 2025. Shares outstanding can be defined as the total number of shares held by all shareholders — including institutional investors, retail investors, and company insiders — assuming conversion of all convertible debt, securities, warrants, and options. This metric excludes the company's treasury shares.

Opus Genetics, Inc. shares outstanding for the fiscal year ending December 31, 2025 were 622.2M, a 2229.05% increase year-over-year. Opus Genetics, Inc. FY 2025 shares outstanding were 622.2M, a +2229.05% increase from FY 2024.

Opus Genetics, Inc. is a leading company operating in the Healthcare sector. The company's share count trajectory — with a 10-year CAGR of — — is a key signal for investors evaluating capital return policy, EPS accretion, and long-term shareholder value creation.

Figures tie to SEC 10-K/10-Q income statement disclosures and FMP /income-statement · /shares-float where noted.

Frequently asked questions

IRD shares outstanding · 4 questions

As of December 31, 2025, Opus Genetics, Inc. (IRD) has approximately 622.2M basic shares outstanding and 622.2M diluted shares outstanding. This represents a +2229.05% year-over-year increase from FY 2024 (26.7M). The increase may reflect equity compensation issuances or secondary offerings.

IRD shares outstandinghow many shares does IRD haveIRD basic shares 2025IRD diluted shares

Data: FMP /income-statement · /shares-float · SEC EDGAR · weighted average basis · Opus Genetics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: 2026-06-09